Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N3O4S |
Molecular Weight | 349.405 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CCC=CC3)C(O)=O
InChI
InChIKey=RDLPVSKMFDYCOR-UEKVPHQBSA-N
InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
Molecular Formula | C16H19N3O4S |
Molecular Weight | 349.405 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
30.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.61 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Concentration-dependent preferences of absorptive and excretive transport cause atypical intestinal absorption of cyclic phenylalanylserine: small intestine acts as an interface between the body and ingested compounds. | 2002 |
|
[Tryptase and fatal anaphylaxic reaction]. | 2002 Aug |
|
Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy. | 2002 Feb 1 |
|
[Empirical therapy of peritonitis in peritoneal dialysis patients--it is reasonable to use a new therapeutic schedule?]. | 2002 Nov |
|
Prolonged intestinal absorption of cephradine with chitosan-coated ethylcellulose microparticles in rats. | 2002 Nov |
|
Treatments for symptomatic urinary tract infections during pregnancy. | 2003 |
|
Uptake of dipeptide and beta-lactam antibiotics by the basolateral membrane vesicles prepared from rat kidney. | 2003 Jan 10 |
|
Sensitive determination of a beta-lactam antibiotic, cefaclor by liquid chromatography with chemiluminescence detection. | 2003 Jan 15 |
|
An interrupted time series analysis of parenteral antibiotic use in Colombia. | 2003 Oct |
|
Re: "Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol" Solis et al. (Pediatr Pulmonol 2003;36: 189-195). | 2004 Sep |
|
Purification and characterization of inducible cephalexin synthesizing enzyme in Gluconobacter oxydans. | 2005 Mar |
|
[Bacterial pathogens and resistance patterns in community acquired pediatric urinary tract infection: experience of 152 cases]. | 2006 Apr |
|
Controlled drug delivery system based on magnetic hollow spheres/polyelectrolyte multilayer core-shell structure. | 2006 Sep-Oct |
|
Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates. | 2007 Oct |
|
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. | 2008 Aug |
|
Human case of Rickettsia felis infection, Taiwan. | 2008 Dec |
|
[Prophylactic use of antibiotics in selective colorectal operation: a randomized controlled trial]. | 2008 Jan 15 |
|
Aeromonas salmonicida peritonitis after eating fish in a patient undergoing CAPD. | 2008 May-Jun |
|
Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations. | 2009 |
|
High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China. | 2009 May |
|
Colorimetric detection of cephradine in pharmaceutical formulations via fluorosurfactant-capped gold nanoparticles. | 2010 Apr 15 |
|
Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns. | 2010 Jan |
|
A survey of the management of urinary tract infection in children in primary care and comparison with the NICE guidelines. | 2010 Jan 26 |
Patents
Sample Use Guides
For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours.
For lobar pneumonia, the usual dose is 500 mg every 6 hours or 1 g every 12 hours.
For uncomplicated urinary tract infections, the usual dose is 500 mg every 12 hours. In more serious urinary tract infections, including prostatitis, 500 mg every 6 hours or 1 g every 12 hours may be administered.
Larger doses (up to 1 g every 6 hours) may be given for severe or chronic infections.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:07:46 GMT 2023
by
admin
on
Sat Dec 16 17:07:46 GMT 2023
|
Record UNII |
9YA6SX5S4D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
WHO-VATC |
QJ01DB09
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
LIVERTOX |
NBK547862
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
LIVERTOX |
NBK548666
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000175488
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
WHO-ATC |
J01DB09
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
LIVERTOX |
NBK548358
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID4022785
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
254-137-8
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
9YA6SX5S4D
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
576
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
3119
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
100000092817
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
3547
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
m3255
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
3216
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
C76181
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
CEFRADINE
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
38103
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
DB01333
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL1604
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
756672
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
38821-53-3
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY | |||
|
SUB07417MIG
Created by
admin on Sat Dec 16 17:07:48 GMT 2023 , Edited by admin on Sat Dec 16 17:07:48 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|